In another phase I trial study (ChiCTR1800018137), CT103A BCMA-targeted CAR-T cell, another next-generation CAR-T cell, was evaluated in nine patients diagnosed with MM. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.